In silico Molecular Docking Analysis of Imatinib to Target the Marker Proteins of Breast Cancer

V. Senthil Kumar a, T. V. Ajay Kumar b and V. Parthasarathy a*

a Immunology Laboratory, Department of Pharmacy, Annamalai University, Annamalai Nagar-608002, Tamil Nadu, India.

b Azidus Laboratories Ltd., Rathinamangalam, Vandalur, Chennai-600048, Tamil Nadu, India.

Authors’ contributions
This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information
DOI: 10.9734/CJAST/2021/v40i3631579

ABSTRACT
Cancer is an uncontrolled over growth of abnormal cells elsewhere in the body. It is the second leading cause of death globally due to non communicable disease. Among the various types of cancers, the incidence of breast cancer is next to lung cancer. The most commonly used drugs to treat breast cancer are namely, Anastrozole, Arimidex, Letrozol, Imatinib, Tamoxifen, Raloxifene, Toremifene and so on. The hope is to establish the specificity of the drug Imatinib towards the selective potential breast cancers such as mammalian target of rapamycin, (mTOR), human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER), poly (ADP-Ribose) polymerase (PARP) and phosphoprotein 53 (p53). To identify the promising target, the Schrodinger software was utilized for the study. The study helped to evaluate the pharmacokinetic properties and binding efficiency of Imatinib towards the breast cancer proteins. The results of study showed that the Imatinib exhibited better binding affinities to mTOR and HER2 as compared to ER, PARP and P53 proteins. The present study will be more useful to rationalize the anticancer therapy based on the expression levels of the target protein in the cancer microenvironment.

*Corresponding author: Email: vapartha@yahoo.com;
Keywords: Cancer; breast cancer; molecular docking; schrodinger; in silico; imatinib; binding affinities; ADME.

1. INTRODUCTION

Cancer is an uncontrolled over proliferation of abnormal cells in the body. The six most widespread cancer types globally are lung cancer, breast cancer, colorectal cancer, prostate cancer, stomach cancer, and cervical cancer. Among the various types of cancers breast cancer is a highly prevalent and second leading cause of death globally next to lung cancer [1,2,3,4]. It is difficult to treat various cancers using a single drug, since the cancer has a large degree of variability in type of cancers as well as cancer patients [5,6,7]. The breast cancer targeted proteins were Serine-threonine kinase AKT, also known as protein kinase B (PKB), Cyclooxygenase 2 (COX2), Human epidermal growth factor receptor (HER/EGFR/ERBB)), Tumor necrosis factor receptor superfamily member 4 (OX40 or CD134), Programmed death-ligand 1 (PD-L1 or CD274 or B7 homolog 1), Vascular endothelial growth factor receptor 1 (VEGFR1), B7H3 (CD276or B7 homolog 3), Cytotoxic T-lymphocyte antigen 4 (CTLA-4 or CD152), Lymphocyte-activation gene 3 (LAG-3), Tumor protein P53 (p53), Cyclin-dependent kinase 4 (CDK4), Epidermal growth factor receptor (EGFR), The mammalian target of rapamycin (mTOR), Poly (ADP-ribose) polymerase 1 (PARP1), Tumor-necrosis factor related apoptosis-inducing ligand( TRAIL or CD253), Cyclin-dependent kinase 6 (CDK6), The transcription factor NF-κB, and Programmed cell death protein 1 (PD-1 or CD279) [8]. The most commonly used drugs to treat breast cancer are namely, Anastrozole, Arimidex, Letrozole, Imatinib, Tamoxifen, Raloxifene, Toremifene and so on [9,10,11]. The Scientists across the world are focusing their attention to developing an ideal drug to treat breast cancer using various tools. Among these the molecular docking analysis is playing a pivotal role in the process of new drug discovery and to establish drug/molecule and receptor interaction. Hence, in the present study in silico analysis was adopted to establish the degree of specificity between Imatinib and the selective target protein such as mammalian target of rapamycin (mTOR) [12], human epidermal growth factor receptor 2 (HER2) [13], estrogen receptor (ER) [14], poly (ADP-Ribose) polymerase (PARP) [15] and phosphoprotein 53 (p53) [16].

Breast cancer most commonly occurs to women and to a small extent to men as well since the breast is composed of identical tissues in males and females. The occurrence of breast cancer in men is 100 times less common as compared to women, but the statistical survival rate of men was similar to women [17]. With 2.1 million new cases and 0.627 million mortality worldwide in 2018 is the foremost reason for the emergence of seriousness about breast cancer. Breast cancer is sorted out into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (HER 2), which is also known as erythroblastic oncogene B2 (ERBB2). The hormone receptor positive/ERBB2 negative patients are 70%, whereas ERBB2 positive alone accounts for 15-20% patients and the triple-negative is stands for a tumor lacking all three standard molecular markers associated with 15% of patients. During the diagnosis more than 90% of breast cancers are not metastatic and the therapeutic goals are tumor abolition as well as preventing the recurrence [18].

The patients with non-metastatic and hormone receptor positive subtypes of breast cancer are treated with endocrine therapy and a minority of patients receive chemotherapy as well. Whereas, the patients with ERBB2-positive tumors receive ERBB2-targeted antibody or small-molecule inhibitor therapy combined with chemotherapy but the patients with triple-negative tumors receive chemotherapy only. Metastatic breast cancer is treated based on its subtype by extending life and reducing the pain of the symptoms. The mean survival time of patients with metastatic triple negative breast cancer is approximately 1 year, whereas 5 years for other two subtypes of cancer [18]. The important contributing factors associated with breast cancer must be taken into account while developing a new drug therapy. The prolonged exposure to endogenous estrogens leads to an early menarche; late menopause and first childbirth at late age are the most important risk factors for breast cancer. Exogenous hormones also exert a higher risk for breast cancer.

Current scenario on molecular therapies for cancer is aimed to alter the key functional molecules to arrest the progression of cancer cells. The eye catching targets are namely,
platelet-derived growth factor receptors (PDGFRs) and c-Kit (CD117/stem cell factor receptor), which are causing an uneven signaling leads to either over expression or mutation that results tumorigenesis as well as cell proliferation [19].

Imatinib mesylate is a selective inhibitor of the tyrosine receptor kinase namely, PDGFR-β and c-Kit [19]. Imatinib (Gleevec® or Glivec®) is also known as a magical bullet developed by Nicholas Lydon, a biochemist of Ciba-Geigy and the clinical trial was conducted with the patients of chronic myeloid leukemia (CML) by Brian Druker, an oncologist at the Dana-Farber Cancer Institute, Harvard Medical School in USA. Since a successful result in treating the patients of CML, the scientists tried to explore the possibility of using imatinib to treat other types of cancer as well. Later it was proved that imatinib exhibited a miracle effect to treat other types of cancer which express the tyrosine kinases. The targeted therapy of Imatinib is in the form of selective tyrosine kinase inhibitors (TKIs). Hence by targeting the TKls, it is the one of the first cancer therapy to treat various cancers. It is an oral targeted therapy of tyrosine kinases specifically BCR-ABL, c-KIT and PDGFRA. It also shows extraordinary success in chronic myeloid leukaemia (CML) and Gastrointestinal Tumor (GIST). It is also a beneficiary in other tumors caused by the Imatinib-specific abnormalities of platelet derived growth factor receptor A (PDGFR) and tyrosine-protein kinase Kit (c-KIT). It is also proved to be efficient in steroid-refractory chronic graft-versus-host disease because of its anti-PDGFR action [20].

Molecular docking is a pivotal tool used in molecular biology and computer-aided drug design. The objective of ligand-protein docking is to envisage the principal binding mode(s) of a ligand with known three dimensional (3D) structure of a protein. The successful docking protocols efficiently hunt high dimensional spaces with scoring properties, which suitably ranks the molecules/ligands. Docking is also used to execute virtual screening from a library of compounds, sort the results and suggest the structural hypotheses to inhibit the target protein, which is precious in lead optimization [21]. In addition to these, the docking is also employed for a broad set of in vitro assays to identify the key parameters such as lipophilicity, solubility as well as plasma stability during the absorption, distribution, metabolism and excretion of a ligand. These predictions assist the evaluation of the pharmacological parameters of a molecule and serve as a representative before it enters In vivo testing as well as clinical trials [22]. The computational protocol predicts probable ADME, toxicity issues and sinking the count of experiments that involve animal testing [23].

The present study is focused on in silico molecular docking analysis of Imatinib on breast cancer specific proteins such as mTor, HER2, ER, PARP and P53 using Schrödinger software. These proteins were mined from protein data bank (PDB) and their identities (ID) are: 3jbz, 3pp0, 3ert, 2rcw and 2x0w respectively. In addition to these, the drug likeness as well as their absorption, distribution, metabolism, and excretion (ADME) properties of Imatinib was also predicted using Lipinski rule.

2. MATERIALS AND METHODS

2.1 Preparation and Protein

Three dimensional (3D) crystal structure of the proteins namely, mammalian target of rapamycin (PDB ID: 3JBZ), epidermal growth factor receptor 2 (PDB ID: 3PP0), estrogen receptor (ER) (PDB ID: 3ERT), poly (ADP-ribose) polymerase (PDB ID: 2RCW) and phosphoprotein 53 (PDB ID: 2X0W). The resolution of these proteins are: 28.0 Å [24], 2.25 Å [25], 1.90 Å [26], 2.80 Å [27] and 2.10 Å [28] respectively. The proteins were mined from protein data bank (PDB) (https://www.rcsb.org). The 3D structures of the proteins were imported into “Protein preparation wizard” [20]. The protein was designed in such a way using appropriate modeling calculations of Schrodinger software.

The protein structure mined from the protein data bank contains heavy atoms, metal ions, missing hydrogen atoms, water molecules, co-crystallized ligand, incomplete and terminal amide groups. The wizard repair the bond orders, formal changes, adding the missing protons, metals treated, and the water beyond the 5Å from the hetero atom was removed. The probable ionization states were created for the ligand in the protein and the most stable state was preferred using Epik [29]. Finally, a controlled minimization of the protein was carried using the force field OPLS-2005 by a limited root mean square deviation (RMSD) tolerance of 0.3 Å [30].

2.2 Receptor Grid Generation

The ligands found in all proteins were retained and the grid was generated over the ligand
associated with an active site using the “receptor grid generation” module of Schrodinger software. The formation of centroid (cubical) shape over the ligand points out the active site of the protein [7,31].

2.3 Preparation of Ligand

The structure and molecular formula (C_{29}H_{31}N_{7}O) of Imatinib was obtained from the “PubChem” using the web link (https://pubchem.ncbi.nlm.nih.gov/compound/Imatinib) (Fig. 1) and saved in .SDF format. Then the ligand was imported into the “LigPrep” module of Schrodinger 2018.1. The 2D structure of the molecule was converted into a low energy 3D structure [31]. In addition to these, the multiple structures with possible ionization states, tautomers, stereo-isomers, and ring conformations were also created. Moreover, the ligand was energy minimized and optimized for their geometry. Using the “EPIK” module the ionization and tautomeric states were created at the pH between 6.8 to 7.2. Finally, the compounds were minimized using optimized potentials for liquid simulations-2005 (OPLS-2005) force field with a root mean square deviation (RMSD) of 1.8 Å was attained [32].

2.4 Molecular Docking

The docking was performed using the “Glide” module of Schrodinger using the previously set receptor grid and ligand. The positive interactions between the ligand molecules were ranked using Glide “Ligand docking” program. The calculations concerning docking were achieved using the extra precision (XP) form and force field OPLS-2005. The flexible docking mode was performed to evaluate the ligand interaction with the receptor and the docking poses were undergoing a sequence of hierarchical filters. The algorithm identifies the good hydrophobic, hydrogen bonding and metal ligation interactions as well as penalizes the steric clashes. Followed by the final stage of the algorithm, minimization was performed using force field OPLS-2005 and the minimized poses were re-ranked with e Glide “Scoring function” [33].

2.5 Lipinski Rule and the Analysis of ADME Properties

The in silico analysis is a vital tool, which is employed for the early preclinical evaluation of a new chemical entity so as to avoid the failure of a molecule at the terminal stage of a drug discovery process. This technique considerably reduces the quantity of time, resources and rationalizes the entire expansion procedures of a new drug molecule. Almost 40% of drug candidates are unsuccessful due to their deprived absorption, distribution, metabolism and excretion (ADME) properties. Hence, the high-throughput screening (HTS) techniques are used to accurately predict the ADME parameters of a newly developed molecule and to screen the tricky drug candidates, which are not worthy to proceed further. Interestingly, this tool is used to redesign the failed compound to increase its preferred parameters to pass all ADME parameters [34].

![Fig. 1. The structure of Imatinib](image-url)
The bioavailability of a molecule is predicted more efficiently using Lipinski’s rule of five, which is recognized as a filter of choice. The five rules denotes that the compound should have a molecular mass of less than 500 daltons, no additional 5 hydrogen bond donors, not more than 10 hydrogen bond acceptors and an octanol/water partition coefficient “log P” should not be greater than 5 [35]. The Lipinski’s rule and pharmacokinetic parameters such as absorption, distribution, metabolism, and excretion (ADME) were predicted using the “QikProp” tool of Schrodinger 2018.1 [36,37].

3. RESULTS AND DISCUSSION

The molecular docking studies on the active sites of various target proteins in breast cancer and the ligand “Imatinib” was conducted using an advanced molecular docking tool “Schrodinger maestro version 11”. The ligand Imatinib was prepared using the “LigPrep” tool of Schrodinger software and the optimized ligand was used for the docking analysis. The breast cancer proteins mTOR, HER2, ER, PARP and P53 were prepared using the protein preparation wizard tool of Schrodinger. The cube shape of the grid/active site region was generated using the receptor grid generation mode of Schrodinger. The generated Grid region/active site was selected and set accordingly to bind/interact with the “Imatinib”, the drug of our interest. The study assessed the affinity of Imatinib towards all the target proteins and ranked the binding affinity.

The molecular docking was performed with all target proteins namely, mTOR, HER2, ER, PARP and P53 using the GLIDE tool of Schrodinger. The predicted docking score, Glide evdw (Van Der Waals energy), ecoul (Coulomb energy), Glide energy and the interacting residues (Hydrogen bond/π-π bond) with target proteins were evaluated in detail to establish the degree of interaction between the target proteins and Imatinib. The results of the study showed that the ligand “Imatinib” perfectly docked and exhibited good binding interactions with the active sites of all the proteins. Results concerning mTOR, HER2, ER, PARP and P53 were referred to as A, B, C, D and E respectively (Table 1).

The results of the present study showed that the Imatinib exhibited good interaction with all the target proteins and the order of binding is mTOR>HER2>ER>PARP>P53. The docking scores of the proteins are -8.3, -8.1, -6.9, -5.3, and-5.2 respectively. The ligands which score the lowest binding energy are considered as a choice of high binding affinity. In the present study mTOR and HER2 showed higher binding affinities with imatinib as compared to ER, PARP and P53 proteins.

The Glide evdw values of the proteins mTOR, HER2, ER, PARP and P53 were -47.63,-46.32, -49.54, -46.44 and -28.58 respectively (Table 1). The Glide ecoul values were -9.8, -10.71, 0.79, -11.64 and -6.55 respectively. Followed by the glide energy of the proteins such as mTOR, HER2, ER, PARP, P5 were also estimated and the scores are -57.45, -57.03, -48.75, -58.07 and -35.14 respectively. The amino acids of the target proteins namely, mTOR, HER2, ER, PARP and P53 demonstrated good interaction with Imatinib through hydrogen bonding, π-π bond and polar interactions. The hydrogen bonds and π-π interactions between the amino acids of target proteins and Imatinib is given in Table 1.

Table 1. The docking score, Glide evdw (Van Der Waals energy), ecoul (Coulomb energy), interacting residues and the type of interaction of Imatinib with breast cancer marker proteins. The docking scores calculated using Glide program of Schrodinger 2018.1. Where, HB denotes hydrogen bonding; Pi-Pi denotes π-π bond

| Name of the drug | Target protein | Docking Score | Glide evdw | Glide ecoul | Glide energy | Interacting residues/type (HB/Pi-Pi) |
|------------------|----------------|---------------|------------|-------------|--------------|------------------------------------|
| Imatinib         | MTOR           | -8.3          | -47.63     | -9.8        | -57.45       | CYS2243/ASP2252/ LYS2187 and TRP 2239 |
|                  | HER2           | -8.1          | -46.32     | -10.71      | -57.03       | THR862, HOH129 and ASP808/ LYS753   |
|                  | ER             | -6.9          | -49.54     | 0.79        | -48.75       | LEU525                             |
|                  | PARP           | -5.3          | -46.44     | -11.64      | -58.07       | GLY227, TYR228 and ARG217/ TYR235 and ARG217 |
|                  | P53            | -5.2          | -28.58     | -6.55       | -35.14       | HOH2254 and HOH20276               |
3.1 Validation of the Docking Programme

The precision of the docking protocol was resolved by analyzing the binding conformation of the ligand and target proteins based on lowest energy poses using the scoring function. The Glide/docking score resembles the experimental binding as determined by X-ray crystallography. The results of the study were calculated using hydrogen bonding interactions, the root mean square deviation (RMSD) between the predicted and the experimental X-ray crystallographic conformations. Here the extra precision (XP) docking mode was demonstrated by taking away the co-crystallized ligand in its active site by docking "Imatinib" with its binding site [31].
docking scores of each target protein with “Imatinib” were compared. Interestingly, “Imatinib” showed a good binding interaction/affinity towards all the five breast cancer specific proteins and the order of binding interaction is as follows: mTOR>HER2>ER>PARP>P53.

![Fig. 3. Binding orientations of Imatinib with the crystal structure of PARP (D), P53 (E), and its hydrogen bond interactions with amino acids](image)

Table 2. The scores of Imatinib predicted by a QikProp module of Schrodinger based on the Lipinski rule. Where MW denotes molecular weight, HB-Hydrogen bond, QPLogP (O/W) - predicted octanol/water partition co-efficient logP respectively

| Name of the Drug | MW (<500) | HB-Donor (<5) | HB-Acceptor (<10) | QPLogP (O/W) (<5) | Rule of 5 (0) |
|------------------|-----------|---------------|-------------------|------------------|--------------|
| Imatinib         | 493.61    | 2             | 10.5              | 3.70             | 0            |

Table 3. Predicted ADME values of Imatinib using a QikProp module of Schrodinger. Where, QPlogS denotes aqueous solubility, QpHERG-predicted IC₅₀ value for blockage of HERG K⁺ channels, QPlogBB-Brain/blood partition coefficient, PHOA- Predicted human oral absorption, QPPCaco- gut-blood barrier/cell permeability in nm/s respectively

| Name of the Drug | Pharmacokinetic properties |
|------------------|----------------------------|
|                  | QPlogS (-6.5 to 0.5) | QpHERG (<5) | QPlogBB (-3 to 1.2) | PHOA (>80 high, < 25 poor) | QPPCaco (>500 high, <25 poor) |
| Imatinib         | -5.25 | -9.61 | 0.33 | 81 | 66 |
3.2 Lipinski Rule and ADME Properties

The ADME properties of the test drug “Imatinib” was further assessed based on Lipinski’s rule using the QikProp module of Schrodinger software. The Lipinski’s properties such as molecular weight, hydrogen bond donor (HBD), hydrogen bond acceptor (HBA), partition coefficient (QclogP (O/W) and the rule of five. The estimated values of the above parameters were 493.61 (<500), 2 (<5), 10.5 (<10), 3.70 (<5) and the rule of 5 is 0 (0) respectively (Table 2). The predicted Lipinski values were below the limit given within the parentheses except a minor variation observed with HBA.

The Pharmacokinetic parameters such as aqueous solubility (QclogS), Predicted IC_{50} value for blockage of HERG K^+ channels (QclogHERG), Predicted brain/blood partition coefficient (QclogBB), Predicted qualitative human oral absorption (PHOA) and gut-blood barrier/cell permeability in nm/s (QPPCaco) were calculated. The corresponding values are, -5.25 (-6.5 to 0.5), -9.61 (<-5), 0.33 (-3 to 1.2), 81 (>80 high, < 25 poor), and 66 (>500 high, <25 poor) respectively (Table 3). The pharmacokinetic properties of Imatinib exhibited that the values were within the acceptable range and not deviated from the limit. From the overall study, the in silico analysis of Imatinib showed a good interaction with the target protein and qualified to all the parameters of Lipinski’s rule and ADME.

4. CONCLUSION

The present study evaluated the molecular interaction and the pharmacokinetic analysis of Imatinib with the selected proteins namely mTOR, HER2, ER, PARP and P53 using Schrodinger Maestro. The programs namely, GLIDE and QikProp of Schrodinger were used to analyze the binding affinity as well as ADME properties. The results of the study showed good binding interaction/affinity through hydrogen bond, polar and the pi-pi bonds interactions with the respective proteins. Interestingly, the predicted scores for the drug Imatinib by Lipinski’s rule and ADME properties were in acceptable range. To conclude this, the drug Imatinib effectively inhibits the target breast cancer proteins such as mTOR, HER2, ER, PARP and P53 with low energy. The interaction energies of Imatinib with the five proteins were in the increasing order of mTOR > HER2 > ER > PARP > P53. Additionally, the proteins mTOR and HER2 showed better binding affinities towards Imatinib as compared to ER, PARP and P53 proteins. The present study will be more useful to rationalize the anticancer therapy based on the expression levels of the target protein in the cancer microenvironment.

DISCLAIMER

The products used for this research are commonly and predominantly use products in our area of research and country. There is absolutely no conflict of interest between the authors and producers of the products because we do not intend to use these products as an avenue for any litigation but for the advancement of knowledge. Also, the research was not funded by the producing company rather it was funded by personal efforts of the authors.

ETHICAL APPROVAL

As per international standard or university standard written ethical approval has been collected and preserved by the author(s).

CONSENT

As per international standard or university standard, patients’ written consent has been collected and preserved by the author(s).

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No.11, Fact sheet.
2. Powles TJ, Ashley S, Tidy A, Smith IE, Dowsett M. Twenty-year follow-up of the royal marsden randomized, double-blinded tamoxifen breast cancer prevention trial. Journal of National Cancer Institute. 2007;99(4):283-90. DOI:10.1093/jnci/djk050.
3. Cummings SR, Ensrud K, Delmas PD, LaCroix AZ, Vukicevic S, Reid DM, et al. Pearl study investigators. Lasofoxifene in postmenopausal women with osteoporosis. The New England Journal of Medicine. 2010;362(8):86-96. DOI: 10.1056/NEJMoa0808692.
4. Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. Journal of Clinical Oncology. 2010;28(3):509-18. DOI: 10.1200/JCO.2009.23.1274.

5. GCC Lim. Clinical oncology in Malaysia: 1914 to present. Biomedical Imaging and Intervention Journal. 2006;2(1):e18. DOI: 10.2349/biij.2.1.e18.

6. GCC Lim. Overview of cancer in Malaysia. Japan Journal of Clinical Oncology. 2002;32:37-42. DOI: https://doi.org/10.1093/jcco/hye132.

7. Balachandran P, Ajay Kumar TV, Parthasarathy V. Screening of potential anticancer compounds from Sargassum wightii to target breast cancer specific HER2 receptor using in-silico analysis. The Natural Products Journal. 2016;6(2):108-115. DOI:10.2174/2210315506666160218224112.

8. Anonymous. Available:https://www.sinobiological.com/research/cancer-drug-targets/breast-cancer, Accessed on 03rd December 2021.

9. He T, Yang W, Zhang X, Li P, Yang D, Wu Y, Fan Y, Xiang M, Huang Q, Chen J, Zhou R, Lv Q, Chen J. Comparative effectiveness of tamoxifen, toremifene, letrozole, anastrozole, and exemestane on lipid profiles in breast cancer patients: A network meta-analysis. Medicine. 2020;99(2):e18550. DOI: 10.1097/MD.0000000000018550.

10. Kala V, Nancy E Davidson. Aromatase Inhibitors as adjuvant therapy in breast cancer. Oncology (Williston Park). 2003;17(3):335-354.

11. Cristofanilli M, Morandi P, Krishnamurthy S, Reuben JM, Lee BN, Francis D, Booser D J, Green MC, et al. Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations. Annals of oncology: Official journal of the European Society for Medical Oncology. 2008;19(10):1713-1719. DOI: 10.1093/annonc/mdn352.

12. Mita MM, Mita A, Rowsinsky EK. Mammalian target of Rapamycin: a new molecular target for breast cancer. Clinical Breast Cancer. 2003;4(2):126-137. DOI: https://doi.org/10.1159/000343063.

13. Mirtavoos-Mahyari H, Khosravi A, Esfahani-Monfared Z. Human epidermal growth factor receptor 2 and estrogen receptor status in respect to tumor characteristics in non-metastatic breast cancer. Tannaffos. 2014;13(1):26-34.

14. Lumachi F, Brunello A, Maruzzo M, Basso U, Basso SM. Treatment of estrogen receptor-positive breast cancer. Current Medicinal Chemistry. 2013;20(5):596-604. DOI: 10.2174/092986713804999303.

15. Morales J, Li L, Fattah FJ, Dong Y, Bey EA, Patel M, Gao J, Boothman DA. Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases. Critical Reviews in Eukaryotic Gene Expression. 2014;24(1):15-28. DOI: 10.1615/critreveukaryotgenexpres.2013006875.

16. Davidoff AM, Kerns BJ, Pence JC, Marks JR, Iglehart JD. P53 alterations in all stages of breast cancer. Journal of Surgical Oncology. 1991;48(4):260-267. DOI: 10.1002/jso.2930480409.

17. Anonymous. World Health Organization (WHO). Cancer: Fact Sheet. Feb. 2006:297.

18. Waks AG, Winer EP. Breast cancer treatment: A review. The Journal of the American Medical Association. 2019;321(3):288-300. DOI: 10.1001/jama.2018.19323.

19. Kadivar A, Kamalideghan B, Akbari Javar H, Karimi B, Sedghi R, Noordin MI. Antiproliferation effect of Imatinib mesylate on MCF7, T-47D tumorigenic and MCF10A nontumorigenic breast cell lines via PDGFR-β, PDGF-BB, c-Kit and SCF genes. Drug Design, Development and Therapy. 2017;11:469-481. DOI: 10.2147/DDDT.S124102.

20. Nida Iqbal, Naveed Iqbal. Imatinib: A review. The American Journal of Cancer Research. 2018;2(2):31-42. DOI: 10.4172/2375-4400.1000124.

21. Morris GM, Lim-Wilby M. Molecular docking. Methods in Molecular Biology. 2008;443:365-82. DOI: 10.1007/978-1-59745-177-2_19.

22. Arne K, Vinicius GM, Carsten W, Thales K. ADME profiling in drug discovery and a new path paved on silica, drug discovery and development - new advances. Intechopen. 2019:1-31.
23. Fernando DPM, Edgar LL, Euridice JMK, Jose LMF. Chapter 2 - Computational drug design methods-Current and future perspectives. In silico drug design repurposing techniques and methodologies. 2019:19-44.

DOI: https://doi.org/10.1016/b978-0-12-816125-8.00002-x.

24. Lau WC, Li Y, Liu Z, Gao Y, Zhang Q, Huen MS. Structure of the human dimeric ATM kinase. Cell cycle. 2016;15(8):1117-1124.

DOI: 10.1080/15384101.2016.1158362.

25. Aertgeerts K, Skene R, Yano J, Sang BC, Zou H, Snell G, Jennings A, et al. Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein. Journal of Biological Chemistry. 2011;286(21):18756-65. DOI: 10.1074/jbc.M110.206193.

26. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell. 1998;95(7):927-937.

DOI: s0092-8674(00)81717-1.

27. Park CH. PARP complexed with A620223. Released 23rd Sep. 2008 to be published. DOI: 10.2210/pdb2RCW/pdb.

28. Basse N, Kaar JL, Settanni G, Joerger AC, Rutherford TJ, Fersht AR. Toward the rational design of p53-stabilizing drugs: probing the surface of the oncogenic Y220C mutant. Chemical Biology. 2010;17(1):46-56. DOI: 10.1016/j.chembior.2009.12.011.

29. Shelley JC, Cholleti A, Frye L, Greenwood JR, Timlin MR, Uchimaya M. Epik: a software program for pKa prediction and protonation state generation for drug-like molecules. Journal of Computer aided Molecular Design. 2007;21:681-691. DOI: https://doi.org/10.1007/s10822-007-9133-z.

30. Ajay Kumar TV, Athavan AAS, Loganathan C, Saravanan K, Kabilan S, Parthasarathy V. Design, 3D QSAR modeling and docking of TGF-β type I inhibitors to target cancer. Computational Biology and Chemistry. 2018;76:232-244.

DOI: 10.1016/j.compbiolchem.2018.07.011.

31. Rajagopal K, Sundaram S, Selvaraj J, Byran G. Molecular docking studies and in-silico ADMET screening of some novel oxazine substituted 9-Anilinoacridines as topoisoerase II Inhibitors. Indian Journal of Pharmaceutical Education and Research. 2017;51(1):110-115.

DOI: 10.5530/ijper.51.1.15.

32. Banks JL, Beard HS, Cao Y, Cho AE; Damm W, Farid R, Felts AK, Halgren TA, Mainz DT, Maple JR, Murphy R, Philipp DM, et al. Integrated modeling program, applied chemical theory (IMPACT). Journal of Computational Chemistry. 2005;26:1752-80.

DOI: 10.1002/jcc.20292.

33. Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, Sanschagrin PC, Mainz DT. Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. Journal of Medicinal Chemistry. 2006;49:6177-6196.

DOI: https://doi.org/10.1021/jm051256o.

34. Mullard A. Re-assessing the rule of 5, two decades on. Nature Reviews Drug Discovery. 2018;17(11):777.

DOI: 10.1038/nrd.2018.197.

35. Lipinski CA. Lead and drug-like compounds: the rule-of-five revolution. Drug discovery today: Technologies. 2004;1(4):337-341.

DOI: 10.1016/j.ddtec.2004.11.007.

36. Anonymous. Schrodinger Release 2018-1: QikProp, Schrodinger, LLC, New York, NY, 2018.

37. Anonymous. Schrodinger Release 2018-1: Protein Preparation Wizard; Epik, Schrodinger, LLC, New York, NY, 2018; Impact, Schrodinger, LLC, New York, NY, 2018; Prime, Schrodinger, LLC, New York, NY, 2018.